Bolt Biotherapeutics Inc
BOLT
Market Cap$42.7M
Close$
Share Statistics
| Market cap | $42.70 Million |
|---|---|
| Enterprise Value | $-39,266,931.00 |
| Dividend Yield | $0.0 (0.0%) |
| Earnings per Share | $-1.83 |
| Beta | 1.16 |
| Outstanding Shares | 38,127,740 |
| Avg 30 Day Volume | 87,586 |
Return
| Return on Equity | - |
|---|---|
| Return on Assets | - |
| Return on Invested Capital | - |
Valuation & Multiples
| P/E Ratio | -0.62 |
|---|---|
| PEG | 5.89 |
| Price to Sales | - |
| Price to Book Ratio | 0.67 |
| Enterprise Value to Revenue | -4.99 |
| Enterprise Value to EBIT | 0.52 |
| Enterprise Value to Net Income | 0 |
| Total Debt to Enterprise | -0.51 |
| Debt to Equity | 0.18 |
Revenue Sources
No data
ESG Score
No data
About Bolt Biotherapeutics Inc
65 employeesBolt Biotherapeutics, Inc. is a clinical-stage immuno-oncology company developing tumor-targeted therapies that leverage the power of the innate and adaptive immune systems. Bolt’s proprietary Boltbody™ Immune-stimulating Antibody Conjug...